Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- 52 Pharmacotherapy of Dystonia
- 53 Anticholinergics in the Treatment of Dystonia
- 54 Tetrabenazine for the Treatment of Dystonia
- 55 Treatment of Dopa-Responsive Dystonia
- 56 Treatment of Paroxysmal Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
56 - Treatment of Paroxysmal Dystonia
from Section VII - Pharmacotherapy for Dystonia
Published online by Cambridge University Press: 31 May 2018
Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- 52 Pharmacotherapy of Dystonia
- 53 Anticholinergics in the Treatment of Dystonia
- 54 Tetrabenazine for the Treatment of Dystonia
- 55 Treatment of Dopa-Responsive Dystonia
- 56 Treatment of Paroxysmal Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Treatment of Dystonia , pp. 292 - 296Publisher: Cambridge University PressPrint publication year: 2018
References
Baschieri, F, Batla, A, Erro, R, Ganos, C, Cordivari, C, Bhatia, KP. 2014. Paroxysmal exercise-induced dystonia due to GLUT1 mutation can be responsive to levodopa: a case report. Journal of Neurology 261(3):615–616.CrossRefGoogle ScholarPubMed
Brockmann, K, Dumitrescu, AM, Best, TT, Hanefeld, F, Refetoff, S. 2005. X-linked paroxysmal dyskinesia and severe global retardation caused by defective MCT8 gene. Journal of Neurology 252(6):663–666.Google Scholar
Bruno, MK, Hallett, M, Gwinn-Hardy, K, Sorensen, B, Considine, E, Tucker, S, et al. 2004. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology 63(12):2280–2287.CrossRefGoogle ScholarPubMed
Bruno, MK, Lee, HY, Auburger, GW, Friedman, A, Nielsen, JE, Lang, AE, et al. 2007. Genotype–phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology 68(21):1782–1789.CrossRefGoogle ScholarPubMed
Erro, R, Sheerin, UM, Bhatia, KP. 2014a. Paroxysmal dyskinesias revisited: a review of 500 genetically proven cases and a new classification. Movement Disorders: Official Journal of the Movement Disorder Society 29(9):1108–1116.Google Scholar
Erro, R, Stamelou, M, Ganos, C, Skorvanek, M, Han, V, Batla, A, et al. 2014b. The clinical syndrome of paroxysmal exercise-induced dystonia: diagnostic outcomes and an algorithm. Movement Disorders: Clinical Practice 1(1):57–61.Google Scholar
Guimaraes, J, Vale Santos, J. 2000. Paroxysmal dystonia induced by exercise and acetazolamide. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 7(2):237–240.CrossRefGoogle ScholarPubMed
Lee, G, Huang, Y, Washington, JM, Briggs, NW, Zuo, Z. 2005. Carbamazepine enhances the activity of glutamate transporter type 3 via phosphatidylinositol 3-kinase. Epilepsy Research 66(1–3):145–153.CrossRefGoogle ScholarPubMed
Leen, WG, Mewasingh, L, Verbeek, MM, Kamsteeg, EJ, van de Warrenburg, BP, Willemsen, MA. 2013. Movement disorders in GLUT1 deficiency syndrome respond to the modified Atkins diet. Movement Disorders: Official Journal of the Movement Disorder Society 28(10):1439–1442.CrossRefGoogle ScholarPubMed
Li, HF, Chen, WJ, Ni, W, Wang, KY, Liu, GL, Wang, N, et al. 2013. PRRT2 mutation correlated with phenotype of paroxysmal kinesigenic dyskinesia and drug response. Neurology 80(16):1534–1535.CrossRefGoogle ScholarPubMed
Li, M, Niu, F, Zhu, X, Wu, X, Shen, N, Peng, X, et al. 2015. PRRT2 mutant leads to dysfunction of glutamate signaling. International Journal of Molecular Sciences 16(5):9134–9151.Google Scholar
Mathew, T, Aroor, S, Nadig, R, Sarma, GR. 2012. Lacosamide in paroxysmal kinesigenic dyskinesia. Movement Disorders: Official Journal of the Movement Disorder Society 27(6):801–802.CrossRefGoogle ScholarPubMed
Mencacci, NE, Erro, R, Wiethoff, S, Hersheson, J, Ryten, M, Balint, B, et al. 2015. ADCY5 mutations are another cause of benign hereditary chorea. Neurology 85(1):80–88.CrossRefGoogle ScholarPubMed
Mink, JW. 2015. Treatment of paroxysmal dyskinesias in children. Current Treatment Options in Neurology 17(6):350.CrossRefGoogle ScholarPubMed
Neville, BG, Ninan, M. 2007. The treatment and management of alternating hemiplegia of childhood. Developmental Medicine and Child Neurology 49(10):777–780.Google Scholar
Ramm-Pettersen, A, Nakken, KO, Skogseid, IM, Randby, H, Skei, EB, Bindoff, LA, et al. 2013. Good outcome in patients with early dietary treatment of GLUT-1 deficiency syndrome: results from a retrospective Norwegian study. Developmental Medicine and Child Neurology 55(5):440–447.Google Scholar
Shen, Y, Ge, WP, Li, Y, Hirano, A, Lee, HY, Rohlmann, A, et al. 2015. Protein mutated in paroxysmal dyskinesia interacts with the active zone protein RIM and suppresses synaptic vesicle exocytosis. Proceedings of the National Academy of Sciences of the United States of America 112(10):2935–2941.CrossRefGoogle ScholarPubMed
Suls, A, Dedeken, P, Goffin, K, Van Esch, H, Dupont, P, Cassiman, D, et al. 2008. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain: A Journal of Neurology 131(Pt 7):1831–1844.CrossRefGoogle ScholarPubMed
Verge, CF, Konrad, D, Cohen, M, Di Cosmo, C, Dumitrescu, AM, Marcinkowski, T, et al. 2012. Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency. The Journal of Clinical Endocrinology and Metabolism 97(12):4515–4523.Google Scholar
Yang, Y, Su, Y, Guo, Y, Ding, Y, Xu, S, Jiang, Y, et al. 2012. Oxcarbazepine versus carbamazepine in the treatment of paroxysmal kinesigenic dyskinesia. The International Journal of Neuroscience 122(12):719–722.CrossRefGoogle ScholarPubMed
Yokoyama, CT, Myers, SJ, Fu, J, Mockus, SM, Scheuer, T, Catterall, WA. 2005. Mechanism of SNARE protein binding and regulation of Cav2 channels by phosphorylation of the synaptic protein interaction site. Molecular and Cellular Neurosciences 28(1):1–17.CrossRefGoogle ScholarPubMed